DPTX8743 is a potential first-in-class small molecule modulator of MYC condensates, targeting one of cancer’s most important and historically undruggable drivers. Cancer Research UK’s Centre for Drug Development will fund, sponsor, and execute CTA-enabling studies and a Phase 1/2a clinical trial, with Dewpoint retaining all rights to DPTX8743.